

THE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB IN BIO-NAÏVE AND BIO-EXPERIENCED PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE

Triana Lobaton

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A retrospective Belgian study of 84 IBD patients found vedolizumab demonstrated better overall efficacy in bio-naïve compared to bio-experienced patients, particularly for clinical and endoscopic response after induction.

KEY POINTS

- After vedolizumab induction, bio-naïve patients had significantly higher clinical response rates (60.9% vs 39.1%, $P < 0.001$) and endoscopic response rates (90.3% vs 66.7%, $P = 0.027$) compared to bio-experienced patients.
- Bio-naïve patients had 14.69 times higher odds of achieving clinical response after induction (95%CI 3.12-69.14, $P < 0.001$) in multivariate analysis.
- At one year, clinical response remained higher in bio-naïve patients (82.9% vs 62.5%, $P = 0.039$), and treatment survival was significantly longer (aHR 2.32, 95%CI 1.03-5.23, $P = 0.043$).
- Patients without prior intestinal resection had 4.33 times higher odds of achieving clinical remission at one year (95%CI 1.13-16.59, $P = 0.032$).
- The study included 42 bio-naïve and 42 bio-experienced patients treated from January 2018 to June 2021; bio-experienced patients had longer disease duration and more prior intestinal resections at baseline.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/79158640-743c-11ee-b721-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.